iCAD, Inc. announced it will showcase its advancements in cancer detection and therapy, including ProFound AI and the Xoft Axxent Electronic Brachytherapy (eBx) System, in the iCAD exhibition booth (# S1.C71) at Arab Health 2020 in Dubai from January 27-30. iCAD’s Breast Health Solutions suite includes ProFound AI for Digital Breast Tomosynthesis (DBT), as well as software solutions for 2D mammography and breast density. ProFound AI is a high-performing workflow solution featuring the latest in deep-learning artificial intelligence capabilities. In December 2018, ProFound AI for DBT became the first artificial intelligence software for DBT to be cleared by the U.S. Food and Drug Administration; it was also CE marked and Health Canada licensed that same year. ProFound AI for 2D Mammography was CE marked in July 2019. Intended to be used by radiologists reviewing mammography or DBT images, ProFound AI rapidly and accurately analyzes each individual image, or slice, and identifies potentially malignant lesions. Trained with one of the available image datasets, it provides radiologists with crucial information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and prioritizing caseloads. The technology also allows for continuously improved performance via ongoing product updates. Positive clinical data from a large reader study involving ProFound AI for DBT were recently published in Radiology: Artificial Intelligence. According to study findings, ProFound AI for DBT improved radiologist sensitivity by 8%, reduced unnecessary patient recall rates by 7.2%, and slashed reading time for radiologists by 52.7%. Additionally, ProFound AI for DBT cut reading time by up to 57.4% for radiologists reading cases with dense breasts.